Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07053020CT.gov A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) | — | Not Yet Recruiting | — | — | — |
NCT07498465CT.gov A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia | — | Withdrawn | — | — | — |
NCT07423104CT.gov A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT05554419CT.gov Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) | — | Not Yet Recruiting | — | — | — |
NCT07642453CT.gov VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. | — | Not Yet Recruiting | — | — | — |
NCT07575412CT.gov SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | — | Not Yet Recruiting | — | — | — |
NCT07490288CT.gov Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT07583888CT.gov VABu Conditioning in Elderly AML HSCT | — | Recruiting | — | — | — |
NCT07407140CT.gov VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML | — | Not Yet Recruiting | — | — | — |
NCT07563179CT.gov Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
Show 500 more trialsShow fewer
NCT07514832CT.gov VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial | — | Recruiting | — | — | — |
NCT06930352CT.gov Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy | — | Not Yet Recruiting | — | — | — |
NCT07060001CT.gov Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker | — | Not Yet Recruiting | — | — | — |
NCT07537257CT.gov VEN+IDAC vs IDAC in AML | — | Enrolling By Invitation | — | — | — |
NCT07507760CT.gov Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients | — | Not Yet Recruiting | — | — | — |
NCT07651475CT.gov Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | — | Active Not Recruiting | — | — | — |
NCT07486479CT.gov Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | — | Not Yet Recruiting | — | — | — |
NCT07255872CT.gov A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT07651176CT.gov Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT07651163CT.gov Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | — | Enrolling By Invitation | — | — | — |
NCT07223814CT.gov Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT07425782CT.gov Venetoclax Combined With Azacitidine for Consolidation Therapy in AML | — | Not Yet Recruiting | — | — | — |
NCT07259707CT.gov Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML | — | Recruiting | — | — | — |
NCT05521087CT.gov A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | — | Withdrawn | — | — | — |
NCT07228273CT.gov Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06770257CT.gov Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy | — | Withdrawn | — | — | — |
NCT07211958CT.gov Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation | — | Recruiting | — | — | — |
NCT07059975CT.gov UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | — | Recruiting | — | — | — |
NCT07588360CT.gov Haplo-Cord HSCT for AML/MDS | — | Recruiting | — | — | — |
NCT07007312CT.gov Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | — | Recruiting | — | — | — |
NCT07046078CT.gov Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer | — | Recruiting | — | — | — |
NCT06928662CT.gov Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | — | Recruiting | — | — | — |
NCT07172204CT.gov Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT07451912CT.gov Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML | — | Recruiting | — | — | — |
NCT07244367CT.gov Maintenance Venetoclax in AML Fit Patients | — | Recruiting | — | — | — |
NCT07132684CT.gov Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | — | Recruiting | — | — | — |
NCT07108530CT.gov Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study | — | Recruiting | — | — | — |
NCT07232134CT.gov The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia | — | Recruiting | — | — | — |
NCT07106749CT.gov CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies | — | Recruiting | — | — | — |
NCT07109518CT.gov uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | — | Recruiting | — | — | — |
NCT07153068CT.gov SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies | — | Recruiting | — | — | — |
NCT07078591CT.gov Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | — | Recruiting | — | — | — |
NCT06990321CT.gov Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06533761CT.gov Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | — | Recruiting | — | — | — |
NCT05766514CT.gov Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | — | Withdrawn | — | — | — |
NCT06788756CT.gov L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | — | Recruiting | — | — | — |
NCT06561152CT.gov Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML | — | Recruiting | — | — | — |
NCT06763666CT.gov CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML | — | Not Yet Recruiting | — | — | — |
NCT06697327CT.gov Daunorubicin + Cytarabine + Venetoclax in de Novo AML | — | Enrolling By Invitation | — | — | — |
NCT06744556CT.gov HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | — | Active Not Recruiting | — | — | — |
NCT06744504CT.gov Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 | — | Recruiting | — | — | — |
NCT06504459CT.gov Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML | — | Recruiting | — | — | — |
NCT06810791CT.gov HVA vs IA/DA or VA in the Treatment of ND HR-AML | — | Recruiting | — | — | — |
NCT06313437CT.gov Revumenib in Combination With 7+3 + Midostaurin in AML | — | Recruiting | — | — | — |
NCT06660368CT.gov BCL2i CLAG-M in R/R Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT07514936CT.gov Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | — | Recruiting | — | — | — |
NCT06643962CT.gov Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy | — | Recruiting | — | — | — |
NCT06741722CT.gov Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | — | Recruiting | — | — | — |
NCT06652685CT.gov Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT06497062CT.gov Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05628623CT.gov Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment | — | Not Yet Recruiting | — | — | — |
NCT06561880CT.gov The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation | — | Recruiting | — | — | — |
NCT06635681CT.gov Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML | — | Recruiting | — | — | — |
NCT05554406CT.gov Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | — | Recruiting | — | — | — |
NCT06470841CT.gov CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML | — | Not Yet Recruiting | — | — | — |
NCT05554393CT.gov Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | — | Recruiting | — | — | — |
NCT06007911CT.gov Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT06451861CT.gov Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | — | Recruiting | — | — | — |
NCT06529250CT.gov Intermediate-dose HAD Regimen for CEBPA Double-mutated AML | — | Recruiting | — | — | — |
NCT06621199CT.gov Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML | — | Recruiting | — | — | — |
NCT06621212CT.gov Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML | — | Recruiting | — | — | — |
NCT05886049CT.gov A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease | — | Recruiting | — | — | — |
NCT05564390CT.gov MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | — | Recruiting | — | — | — |
NCT07131059CT.gov MRD-positive AML Clinical Study | — | Recruiting | — | — | — |
NCT06387069CT.gov A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06177067CT.gov Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06928376CT.gov A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | — | Recruiting | — | — | — |
NCT05904106CT.gov Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML | — | Recruiting | — | — | — |
NCT06050941CT.gov Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | — | Not Yet Recruiting | — | — | — |
NCT05829434CT.gov Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS | — | Withdrawn | — | — | — |
NCT06316960CT.gov Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation | — | Recruiting | — | — | — |
NCT06434662CT.gov Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML | — | Recruiting | — | — | — |
NCT06001788CT.gov Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT06394011CT.gov Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients | — | Recruiting | — | — | — |
NCT06345365CT.gov MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT05761171CT.gov A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | — | Active Not Recruiting | — | — | — |
NCT06182592CT.gov A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT06221683CT.gov Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML | — | Recruiting | — | — | — |
NCT06232694CT.gov Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML | — | Recruiting | — | — | — |
NCT07437170CT.gov Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML | — | Active Not Recruiting | — | — | — |
NCT06429098CT.gov Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | — | Recruiting | — | — | — |
NCT06034470CT.gov Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | — | Active Not Recruiting | — | — | — |
NCT06537843CT.gov Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05146739CT.gov Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | — | Active Not Recruiting | — | — | — |
NCT05801835CT.gov A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection | — | Unknown | — | — | — |
NCT05941585CT.gov Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT06084819CT.gov Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05320380CT.gov A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat | — | Withdrawn | — | — | — |
NCT05987696CT.gov Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05955261CT.gov A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | — | Suspended | — | — | — |
NCT05735184CT.gov A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | — | Recruiting | — | — | — |
NCT05875649CT.gov A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure | — | Not Yet Recruiting | — | — | — |
NCT04354025CT.gov Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML | — | Withdrawn | — | — | — |
NCT05712278CT.gov A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT05199051CT.gov A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML | — | Active Not Recruiting | — | — | — |
NCT05260528CT.gov CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics | — | Recruiting | — | — | — |
NCT05805072CT.gov Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients | — | Unknown | — | — | — |
NCT05317403CT.gov Venetoclax to Augment Epigenetic Modification and Chemotherapy | — | Recruiting | — | — | — |
NCT05586074CT.gov HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML | — | Recruiting | — | — | — |
NCT05805098CT.gov Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | — | Recruiting | — | — | — |
NCT06068621CT.gov Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05330377CT.gov GM-CLAG in Relapsed/Refractory FLT3-mutated AML | — | Withdrawn | — | — | — |
NCT05918198CT.gov Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT05726110CT.gov Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT05659992CT.gov Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT05665114CT.gov Natural Killer(NK) Cell Therapy in r/r AML | — | Unknown | — | — | — |
NCT05665075CT.gov Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT05662956CT.gov A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients | — | Completed | — | — | — |
NCT05603884CT.gov VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05583175CT.gov Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | — | Unknown | — | — | — |
NCT05453903CT.gov A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | — | Active Not Recruiting | — | — | — |
NCT05183035CT.gov Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | — | Recruiting | — | — | — |
NCT05657639CT.gov CAV Regimen for R/R AML | — | Recruiting | — | — | — |
NCT05319587CT.gov Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT04628026CT.gov Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | — | Recruiting | — | — | — |
NCT05599360CT.gov Vyxeos for Induction of Low- or Intermediate-risk. | — | Active Not Recruiting | — | — | — |
NCT05456269CT.gov A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | — | Withdrawn | — | — | — |
NCT05361057CT.gov Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients | — | Terminated | — | — | — |
NCT04968015CT.gov Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission | — | Active Not Recruiting | — | — | — |
NCT05342584CT.gov Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS | — | Recruiting | — | — | — |
NCT05362942CT.gov Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT05601466CT.gov Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT05326516CT.gov A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | — | Completed | — | — | — |
NCT05177731CT.gov Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML | — | Active Not Recruiting | — | — | — |
NCT04817241CT.gov Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | — | Active Not Recruiting | — | — | — |
NCT04797767CT.gov Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | — | Recruiting | — | — | — |
NCT04849910CT.gov Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | — | Terminated | — | — | — |
NCT05100303CT.gov A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | — | Unknown | — | — | — |
NCT04898894CT.gov Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT05053425CT.gov Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | — | Unknown | — | — | — |
NCT05029141CT.gov New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04956042CT.gov Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT04778397CT.gov Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated | — | Terminated | — | — | — |
NCT04891757CT.gov FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | — | Active Not Recruiting | — | — | — |
NCT04801797CT.gov Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | — | Active Not Recruiting | — | — | — |
NCT04526795CT.gov Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | — | Terminated | — | — | — |
NCT04752163CT.gov DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT04254640CT.gov Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | — | Unknown | — | — | — |
NCT04214249CT.gov BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04229979CT.gov Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 | — | Active Not Recruiting | — | — | — |
NCT04190550CT.gov Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04659616CT.gov Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT04250051CT.gov Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT04375631CT.gov CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | — | Recruiting | — | — | — |
NCT04687761CT.gov Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | — | Completed | — | — | — |
NCT04509622CT.gov A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT04501120CT.gov Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML | — | Recruiting | — | — | — |
NCT04385290CT.gov Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) | — | Recruiting | — | — | — |
NCT04240002CT.gov A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT04293562CT.gov A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | — | Recruiting | — | — | — |
NCT04275518CT.gov A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | — | Recruiting | — | — | — |
NCT04220684CT.gov Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML | — | Completed | — | — | — |
NCT04415008CT.gov Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04195945CT.gov CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | — | Active Not Recruiting | — | — | — |
NCT04196010CT.gov Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms | — | Terminated | — | — | — |
NCT03983824CT.gov Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT04100330CT.gov A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT04217278CT.gov A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | — | Active Not Recruiting | — | — | — |
NCT04029688CT.gov A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | — | Terminated | — | — | — |
NCT04326439CT.gov AflacLL1901 (CHOA-AML) | — | Terminated | — | — | — |
NCT04158739CT.gov Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03969420CT.gov Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy | — | Terminated | — | — | — |
NCT03765541CT.gov Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT05982756CT.gov Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML | — | Unknown | — | — | — |
NCT04216771CT.gov Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients | — | Unknown | — | — | — |
NCT04112589CT.gov A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment | — | Unknown | — | — | — |
NCT03836209CT.gov Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03926624CT.gov Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | — | Terminated | — | — | — |
NCT03760445CT.gov HDM201 Added to CT in R/R or Newly Diagnosed AML | — | Withdrawn | — | — | — |
NCT04050280CT.gov CLAG-GO for Patients With Persistent, Relapsed or Refractory AML | — | Recruiting | — | — | — |
NCT04047641CT.gov Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Recruiting | — | — | — |
NCT04113616CT.gov An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT04107727CT.gov Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT03897127CT.gov Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | — | Active Not Recruiting | — | — | — |
NCT04069208CT.gov IA14 Induction in Young Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT04061239CT.gov Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML | — | Recruiting | — | — | — |
NCT03860844CT.gov Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03813147CT.gov Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03718143CT.gov AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | — | Terminated | — | — | — |
NCT03724084CT.gov Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | — | Terminated | — | — | — |
NCT04087967CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients | — | Unknown | — | — | — |
NCT04083911CT.gov Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 | — | Unknown | — | — | — |
NCT03701308CT.gov Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT03850535CT.gov A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission | — | Terminated | — | — | — |
NCT03591510CT.gov A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | — | Active Not Recruiting | — | — | — |
NCT03900949CT.gov Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03735446CT.gov Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | — | Terminated | — | — | — |
NCT03634228CT.gov Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02587871CT.gov Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission | — | Withdrawn | — | — | — |
NCT03491579CT.gov Epacadostat, Cladribine and Cytarabine (ECC) in AML | — | Withdrawn | — | — | — |
NCT03504410CT.gov Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML | — | Terminated | — | — | — |
NCT03207334CT.gov iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | — | Withdrawn | — | — | — |
NCT03586609CT.gov Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT03709758CT.gov Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML | — | Active Not Recruiting | — | — | — |
NCT03589729CT.gov Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | — | Recruiting | — | — | — |
NCT03531918CT.gov Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | — | Completed | — | — | — |
NCT03444649CT.gov Epacadostat, Idarubicin and Cytarabine (EIC) in AML | — | Withdrawn | — | — | — |
NCT03250338CT.gov Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML | — | Completed | — | — | — |
NCT03793478CT.gov Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | — | Active Not Recruiting | — | — | — |
NCT03258931CT.gov Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML | — | Completed | — | — | — |
NCT03661515CT.gov Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML | — | Completed | — | — | — |
NCT03568994CT.gov Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT03441048CT.gov Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03459859CT.gov Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | — | Completed | — | — | — |
NCT03563560CT.gov A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03519984CT.gov EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | — | Terminated | — | — | — |
NCT03416179CT.gov A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03330821CT.gov Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03381781CT.gov Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | — | Unknown | — | — | — |
NCT03379727CT.gov Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. | — | Completed | — | — | — |
NCT03092674CT.gov Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03324243CT.gov A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT03985007CT.gov CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03303339CT.gov Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT03182244CT.gov A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation | — | Active Not Recruiting | — | — | — |
NCT03214562CT.gov Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT03298984CT.gov Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | — | Completed | — | — | — |
NCT03118466CT.gov Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03256071CT.gov Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT | — | Unknown | — | — | — |
NCT04024241CT.gov Medium Dose of Cytarabine and Mitoxantrone | — | Unknown | — | — | — |
NCT03194932CT.gov Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | — | Completed | — | — | — |
NCT03263936CT.gov Epigenetic Reprogramming in Relapse/Refractory AML | — | Completed | — | — | — |
NCT03356080CT.gov DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | — | Unknown | — | — | — |
NCT03381118CT.gov Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | — | Terminated | — | — | — |
NCT03164057CT.gov A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03150004CT.gov Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | — | Terminated | — | — | — |
NCT02791919CT.gov Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT03069352CT.gov A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | — | Completed | — | — | — |
NCT03135028CT.gov Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults | — | Terminated | — | — | — |
NCT02666950CT.gov WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02809092CT.gov Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT03053206CT.gov A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT03021330CT.gov Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML | — | Active Not Recruiting | — | — | — |
NCT03031249CT.gov Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia | — | Enrolling By Invitation | — | — | — |
NCT03031262CT.gov Efficacy and Safety of Chidamide in CBF Leukemia | — | Active Not Recruiting | — | — | — |
NCT03055286CT.gov Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | — | Terminated | — | — | — |
NCT02875093CT.gov Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML | — | Terminated | — | — | — |
NCT03045627CT.gov Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | — | Unknown | — | — | — |
NCT03012672CT.gov Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm | — | Completed | — | — | — |
NCT02728050CT.gov Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02954653CT.gov A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02298166CT.gov Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations | — | Terminated | — | — | — |
NCT02921061CT.gov Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | — | Completed | — | — | — |
NCT02635074CT.gov Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03013998CT.gov Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT02527174CT.gov A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT02937662CT.gov Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML | — | Completed | — | — | — |
NCT02756572CT.gov Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms | — | Completed | — | — | — |
NCT02909972CT.gov Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02905994CT.gov Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT02834390CT.gov Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02891278CT.gov Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML | — | Completed | — | — | — |
NCT02873338CT.gov Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT03384225CT.gov CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML | — | Unknown | — | — | — |
NCT03384212CT.gov CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML | — | Unknown | — | — | — |
NCT02835729CT.gov A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02886559CT.gov Chidamide Plus DCAG for Relapsed/Refractory AML | — | Unknown | — | — | — |
NCT02649764CT.gov Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02676323CT.gov Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Terminated | — | — | — |
NCT02413021CT.gov The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | — | Unknown | — | — | — |
NCT02719574CT.gov Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | — | Completed | — | — | — |
NCT02957032CT.gov A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation | — | Terminated | — | — | — |
NCT02724163CT.gov International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia | — | Recruiting | — | — | — |
NCT02520011CT.gov Alvocidib Biomarker-driven Phase 2 AML Study | — | Terminated | — | — | — |
NCT02658487CT.gov Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02686593CT.gov Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML | — | Completed | — | — | — |
NCT02676856CT.gov Hematopoietic Stem Cell Microtransplantation for in AML | — | Unknown | — | — | — |
NCT02198482CT.gov Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT02626338CT.gov Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | — | Completed | — | — | — |
NCT03071276CT.gov Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02779283CT.gov Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT02323607CT.gov Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | — | Completed | — | — | — |
NCT03181815CT.gov Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT02582359CT.gov MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | — | Completed | — | — | — |
NCT02632708CT.gov Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | — | Active Not Recruiting | — | — | — |
NCT02545283CT.gov A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT02521493CT.gov Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | — | Active Not Recruiting | — | — | — |
NCT02680951CT.gov Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT02560025CT.gov Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | — | Completed | — | — | — |
NCT02421939CT.gov A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | — | Completed | — | — | — |
NCT02485353CT.gov Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML | — | Terminated | — | — | — |
NCT02573363CT.gov Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02583893CT.gov Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02576301CT.gov Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS | — | Unknown | — | — | — |
NCT02400281CT.gov Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | — | Completed | — | — | — |
NCT02229266CT.gov Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML | — | Terminated | — | — | — |
NCT02502968CT.gov BL-8040 Addition to Consolidation Therapy in AML Patients | — | Unknown | — | — | — |
NCT02484391CT.gov CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma | — | Completed | — | — | — |
NCT02343939CT.gov Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT02464657CT.gov Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02403310CT.gov A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | — | Completed | — | — | — |
NCT02416908CT.gov Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02532010CT.gov Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML | — | Terminated | — | — | — |
NCT02440568CT.gov AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | — | Terminated | — | — | — |
NCT02433483CT.gov Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients | — | Terminated | — | — | — |
NCT02299518CT.gov Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02109627CT.gov Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | — | Terminated | — | — | — |
NCT02717884CT.gov Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) | — | Unknown | — | — | — |
NCT02419755CT.gov Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | — | Terminated | — | — | — |
NCT02270788CT.gov Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies | — | Completed | — | — | — |
NCT02432911CT.gov Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old | — | Unknown | — | — | — |
NCT02348489CT.gov SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | — | Completed | — | — | — |
NCT02306291CT.gov Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | — | Completed | — | — | — |
NCT02310321CT.gov A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | — | Completed | — | — | — |
NCT02412475CT.gov Epigenetic Reprogramming in Relapse AML | — | Terminated | — | — | — |
NCT02351037CT.gov Study of Ibrutinib in Subjects With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02236013CT.gov A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02255162CT.gov Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML | — | Terminated | — | — | — |
NCT02416388CT.gov Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR | — | Recruiting | — | — | — |
NCT02283177CT.gov A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations | — | Completed | — | — | — |
NCT02287233CT.gov A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | — | Completed | — | — | — |
NCT02323022CT.gov Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02049801CT.gov MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02328950CT.gov A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome | — | Unknown | — | — | — |
NCT02326584CT.gov A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | — | Completed | — | — | — |
NCT02275663CT.gov Azacytidine Plus FLAG for Relapsed or Refractory AML | — | Unknown | — | — | — |
NCT02272478CT.gov Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations | — | Unknown | — | — | — |
NCT02488408CT.gov A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | — | Completed | — | — | — |
NCT02070458CT.gov Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02319135CT.gov Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02249091CT.gov A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT02212561CT.gov Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02013648CT.gov Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) | — | Completed | — | — | — |
NCT02046122CT.gov Adoptive Transfer of Haplo-identical DLI for AML and MDS | — | Completed | — | — | — |
NCT02115295CT.gov Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | — | Recruiting | — | — | — |
NCT01787474CT.gov Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02140606CT.gov Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML) | — | Unknown | — | — | — |
NCT02038777CT.gov A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | — | Completed | — | — | — |
NCT02171117CT.gov Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT02088541CT.gov Selinexor (KPT-330) in Older Patients With Relapsed AML | — | Completed | — | — | — |
NCT01904643CT.gov Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02105116CT.gov AML Therapy With Irradiated Allogeneic Cells | — | Terminated | — | — | — |
NCT02072811CT.gov Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT02044796CT.gov Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT01843179CT.gov Sulindac for Patients With AML | — | Withdrawn | — | — | — |
NCT02029950CT.gov Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01588951CT.gov Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior | — | Terminated | — | — | — |
NCT02056782CT.gov A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01892371CT.gov Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01999413CT.gov Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients | — | Completed | — | — | — |
NCT01853228CT.gov A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01960387CT.gov Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01876953CT.gov Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT02428543CT.gov Ponatinib for FLT3-ITD Acute Myelogenous Leukemia | — | Unknown | — | — | — |
NCT01830777CT.gov Brentuximab Vedotin + Re-induction Chemotherapy for AML | — | Completed | — | — | — |
NCT01870596CT.gov Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01779843CT.gov Alisertib for Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01838395CT.gov Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients | — | Completed | — | — | — |
NCT01801046CT.gov Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01802333CT.gov Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01829503CT.gov Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT01773408CT.gov A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | — | Completed | — | — | — |
NCT01721876CT.gov Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) | — | Completed | — | — | — |
NCT01768897CT.gov CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01729845CT.gov Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT01696084CT.gov Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01701323CT.gov Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01636609CT.gov Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | — | Terminated | — | — | — |
NCT02084563CT.gov Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms | — | Completed | — | — | — |
NCT02575963CT.gov Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients | — | Completed | — | — | — |
NCT01681537CT.gov Lenalidomide Plus Chemotherapy for AML | — | Completed | — | — | — |
NCT01641250CT.gov A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | — | Completed | — | — | — |
NCT01621477CT.gov T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | — | Terminated | — | — | — |
NCT01607645CT.gov Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | — | Terminated | — | — | — |
NCT01435343CT.gov Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | — | Completed | — | — | — |
NCT01635296CT.gov A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | — | Completed | — | — | — |
NCT01546038CT.gov A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01839240CT.gov Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01477606CT.gov Protocol in Acute Myeloid Leukemia With FLT3-ITD | — | Completed | — | — | — |
NCT04687098CT.gov Risk-adapted Therapy for Primary Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01455025CT.gov Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT00967512CT.gov Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course | — | Withdrawn | — | — | — |
NCT01534702CT.gov Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML | — | Unknown | — | — | — |
NCT01463046CT.gov Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT01478074CT.gov ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT01500161CT.gov Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | — | Terminated | — | — | — |
NCT01555268CT.gov Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01390337CT.gov A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT01484171CT.gov HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT01371981CT.gov Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01423175CT.gov ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS | — | Unknown | — | — | — |
NCT01398462CT.gov Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | — | Completed | — | — | — |
NCT01947322CT.gov Haploidentical NK-cell Infusion in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01237808CT.gov Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | — | Completed | — | — | — |
NCT01246752CT.gov Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) </= 60y. After First CR | — | Terminated | — | — | — |
NCT00906945CT.gov Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01265199CT.gov Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML) | — | Terminated | — | — | — |
NCT01249430CT.gov Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01191801CT.gov Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | — | Completed | — | — | — |
NCT01238211CT.gov Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01296178CT.gov PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years | — | Unknown | — | — | — |
NCT01180322CT.gov Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | — | Completed | — | — | — |
NCT01161550CT.gov Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML | — | Completed | — | — | — |
NCT01222143CT.gov Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01193400CT.gov Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years | — | Terminated | — | — | — |
NCT01158885CT.gov Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia | — | Terminated | — | — | — |
NCT01187810CT.gov Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | — | Terminated | — | — | — |
NCT01174888CT.gov Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01184898CT.gov Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
NCT01127009CT.gov Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01074047CT.gov Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00943553CT.gov A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects | — | Withdrawn | — | — | — |
NCT01130506CT.gov Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT00893399CT.gov Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation | — | Completed | — | — | — |
NCT01027923CT.gov IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT01132586CT.gov Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01067274CT.gov ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) | — | Withdrawn | — | — | — |
NCT01066494CT.gov A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | — | Unknown | — | — | — |
NCT01587430CT.gov 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia | — | Unknown | — | — | — |
NCT01056523CT.gov Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01034410CT.gov A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01025154CT.gov Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction | — | Completed | — | — | — |
NCT01031368CT.gov Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT01698879CT.gov Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment | — | Completed | — | — | — |
NCT00908167CT.gov Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | — | Completed | — | — | — |
NCT00995332CT.gov Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine | — | Completed | — | — | — |
NCT00907517CT.gov Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) | — | Terminated | — | — | — |
NCT00939653CT.gov T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) | — | Terminated | — | — | — |
NCT00915252CT.gov Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00952588CT.gov Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients | — | Completed | — | — | — |
NCT00831766CT.gov Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00850382CT.gov Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00926731CT.gov Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) | — | Completed | — | — | — |
NCT00932412CT.gov The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial) | — | Completed | — | — | — |
NCT03961919CT.gov Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant | — | Completed | — | — | — |
NCT00863434CT.gov Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease | — | Terminated | — | — | — |
NCT02144675CT.gov Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00804856CT.gov Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia | — | Completed | — | — | — |
NCT00839982CT.gov Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS | — | Completed | — | — | — |
NCT00634244CT.gov Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00788892CT.gov Trial of CPX-351 in Newly Diagnosed Elderly AML Patients | — | Completed | — | — | — |
NCT00778375CT.gov Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT00703820CT.gov Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00632749CT.gov BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment | — | Completed | — | — | — |
NCT00656617CT.gov Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00666588CT.gov Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00620321CT.gov A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00655395CT.gov Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine | — | Terminated | — | — | — |
NCT00927498CT.gov A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old | — | Completed | — | — | — |
NCT00602225CT.gov Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00594555CT.gov A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | — | Withdrawn | — | — | — |
NCT00593645CT.gov Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | — | Terminated | — | — | — |
NCT00541866CT.gov Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans | — | Completed | — | — | — |
NCT00513305CT.gov Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT00542971CT.gov Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | — | Completed | — | — | — |
NCT00528333CT.gov A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML | — | Completed | — | — | — |
NCT06211452CT.gov Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00780104CT.gov Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | — | Completed | — | — | — |
NCT00512252CT.gov AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00470197CT.gov Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | — | Completed | — | — | — |
NCT00422591CT.gov Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00317642CT.gov A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | — | Completed | — | — | — |
NCT02182596CT.gov DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML | — | Completed | — | — | — |
NCT00357305CT.gov Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | — | Completed | — | — | — |
NCT02831192CT.gov Microtransplantation in Older Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00569010CT.gov Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | — | Completed | — | — | — |
NCT00273884CT.gov Amonafide in Combination With Cytarabine in Secondary AML | — | Completed | — | — | — |
NCT00334074CT.gov Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS | — | Completed | — | — | — |
NCT00382590CT.gov Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | — | Completed | — | — | — |
NCT01497002CT.gov Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a | — | Completed | — | — | — |
NCT00529880CT.gov Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML | — | Unknown | — | — | — |
NCT00098423CT.gov Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | — | Completed | — | — | — |
NCT00088218CT.gov Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS). | — | Completed | — | — | — |
NCT00744081CT.gov Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00151242CT.gov Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00143975CT.gov Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) | — | Completed | — | — | — |
NCT00151255CT.gov All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT02461121CT.gov HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk | — | Completed | — | — | — |
NCT00074737CT.gov Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | — | Completed | — | — | — |
NCT00093600CT.gov PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00081822CT.gov Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00077181CT.gov 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies | — | Completed | — | — | — |
NCT00180102CT.gov AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years | — | Completed | — | — | — |
NCT00067028CT.gov Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) | — | Completed | — | — | — |
NCT00079482CT.gov Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT01723657CT.gov Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) | — | Completed | — | — | — |
NCT00070551CT.gov GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00195000CT.gov Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS | — | Completed | — | — | — |
NCT00774046CT.gov High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML | — | Completed | — | — | — |
NCT00136084CT.gov Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia | — | Completed | — | — | — |
NCT00304447CT.gov Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia | — | Completed | — | — | — |
NCT00186966CT.gov Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00161668CT.gov Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care | — | Completed | — | — | — |
NCT00474006CT.gov High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML | — | Completed | — | — | — |
NCT00583102CT.gov Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML | — | Terminated | — | — | — |
NCT00038831CT.gov Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | — | Completed | — | — | — |
NCT00016016CT.gov Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | — | Completed | — | — | — |
NCT00037596CT.gov Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00368355CT.gov T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts | — | Completed | — | — | — |
NCT00199147CT.gov Efficacy of G-CSF-Priming in Elderly AML Patients | — | Unknown | — | — | — |
NCT00266136CT.gov Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | — | Completed | — | — | — |
NCT00209833CT.gov Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T | — | Unknown | — | — | — |
NCT00464217CT.gov Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years | — | Completed | — | — | — |
NCT00487448CT.gov SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | — | Completed | — | — | — |
NCT00146120CT.gov Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result | — | Completed | — | — | — |
NCT00925873CT.gov GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly | — | Completed | — | — | — |
NCT00480064CT.gov Lomustine and Intermediate Dose Cytarabine in Older Patients With AML | — | Completed | — | — | — |
NCT00136448CT.gov High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) | — | Completed | — | — | — |
NCT01039363CT.gov Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytarabine (this asset) | M.D. Anderson Cancer Center | Approved | BB · 67 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | A |
| Amsacrine | University Hospital, Toulouse | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Alvocidib | M.D. Anderson Cancer Center | P2 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
| Therapeutic Allogeneic Lymphocytes | University of Southern California | P2 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Cytarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cytarabine in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cytarabine-acute-myeloid-leukemia-63028
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →